Inozyme Pharma Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	Current	2023	2022	2021	2020
Market Capitalization	274	263	42	161	482
Market Cap Growth	-	520.31%	-73.72%	-66.54%	-
Enterprise Value	132	121	-79	53	336
PE Ratio	-3.70	-3.70	-0.63	-2.85	-8.55
PB Ratio	1.95	1.87	0.36	1.48	3.05
P/FCF Ratio	-3.71	-3.71	-0.73	-3.32	-13.20
P/OCF Ratio	-3.72	-3.72	-0.73	-3.35	-13.41
EV/EBITDA Ratio	-1.82	-1.82	1.20	-0.95	-5.97
EV/EBIT Ratio	-1.78	-1.78	1.18	-0.94	-5.95
EV/FCF Ratio	-1.70	-1.70	1.36	-1.09	-9.19
Debt / Equity Ratio	0.33	0.33	0.06	0.03	0.01
Debt / EBITDA Ratio	-0.70	-0.70	-0.10	-0.06	-0.02
Debt / FCF Ratio	-0.66	-0.66	-0.12	-0.07	-0.04
Quick Ratio	12.86	12.86	8.71	9.61	14.85
Current Ratio	13.36	13.36	8.93	9.91	15.14
Interest Coverage	-20.35	-20.35	-254.96	-	-
Return on Equity (ROE)	-55.90%	-55.90%	-54.00%	-43.40%	-96.00%
Return on Assets (ROA)	-40.70%	-40.70%	-47.50%	-39.80%	-49.20%
Return on Capital (ROIC)	-40.44%	-40.44%	-54.86%	-50.29%	-35.79%
Earnings Yield	-25.95%	-27.05%	-158.11%	-35.08%	-11.70%
FCF Yield	-25.88%	-26.98%	-137.15%	-30.08%	-7.57%
Buyback Yield / Dilution	-37.27%	-37.27%	-60.30%	-113.46%	-832.81%
Total Shareholder Return	-37.27%	-37.27%	-60.30%	-113.46%	-832.81%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).